Participants with adverse events ‐ potential immune‐mediated disease Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ potential immune‐mediated… compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ any local symptom Clinical criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any local symptomClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review
Dropouts ‐ did not receive second dose Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher dropouts ‐ did not receive second doseClinical or laboratory criteria compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine probably leads to higher participants with adverse eventsClinical or laboratory criteria compared with placebo (moderate certainty).
1 finding from 1 review
DeathClinical criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in deathClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review
Systemic adverse events at · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in participants with adverse events ‐ systemic adverse eventsClinical… compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ injection site adverse events Clinical criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine probably leads to higher participants with adverse events ‐ injection site adverse… compared with placebo (moderate certainty).
1 finding from 1 review
Dropouts Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in dropoutsClinical or laboratory criteria compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ death Clinical criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ deathClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review
Iron deficiency (as defined by study authors, based on a biomarker of iron status) · population aged 2 years and above (Andersson 2008 ‐ 5‐18 years, Asibey‐Berko 2007 ~ 3 years, Chen Ke 2008 ‐ 2‐6 years, Haas 2014 ‐ women…
Condiments/seasonings fortified with iron plus other micronutrients may leads to lower iron deficiency (as defined by the trialists based on a biomarker of… compared with condiments/seasonings fortified with other micronutrients except iron (low certainty).
1 finding from 1 review
Ferritin (µg/L) · population aged 2 years and above (Andersson 2008 ‐ 5‐18 years, Asibey‐Berko 2007 ~ 3 years, Chen Ke 2008 ‐ 2‐6 years, Haas 2014 ‐ women…
1 finding from 1 review
Transferrin saturation · population aged 2 years and above (Andersson 2008 ‐ 5‐18 years, Asibey‐Berko 2007 ~ 3 years, Chen Ke 2008 ‐ 2‐6 years, Haas 2014 ‐ women…
1 finding from 1 review
Total iron binding capacity · population aged 2 years and above (Andersson 2008 ‐ 5‐18 years, Asibey‐Berko 2007 ~ 3 years, Chen Ke 2008 ‐ 2‐6 years, Haas 2014 ‐ women…
1 finding from 1 review
Adverse effects · population aged 2 years and above (Andersson 2008 ‐ 5‐18 years, Asibey‐Berko 2007 ~ 3 years, Chen Ke 2008 ‐ 2‐6 years, Haas 2014 ‐ women…
1 finding from 1 review
Haemoglobin (g/dL) · population aged 2 years and above (Ballot 1989a (C) ‐ > 10 years, Chen 2005 (C) ‐ >3 years; Huo 2002 ‐ 11‐17 years, Longfils 2008‐ 6‐21…
1 finding from 1 review
Iron deficiency (as defined by study authors, based on a biomarker of iron status) · population aged 2 years and above (Ballot 1989a (C) ‐ > 10 years, Chen 2005 (C) ‐ >3 years; Huo 2002 ‐ 11‐17 years, Longfils 2008‐ 6‐21…
Condiments/seasonings fortified with iron showed no clear difference in iron deficiency (as defined by the trialists based on a biomarker of… compared with unfortified condiments/seasonings (moderate certainty).
1 finding from 1 review
Ferritin (µg/L) · population aged 2 years and above (Ballot 1989a (C) ‐ > 10 years, Chen 2005 (C) ‐ >3 years; Huo 2002 ‐ 11‐17 years, Longfils 2008‐ 6‐21…
1 finding from 1 review
Transferrin saturation · population aged 2 years and above (Ballot 1989a (C) ‐ > 10 years, Chen 2005 (C) ‐ >3 years; Huo 2002 ‐ 11‐17 years, Longfils 2008‐ 6‐21…
1 finding from 1 review
Total iron binding capacity · population aged 2 years and above (Ballot 1989a (C) ‐ > 10 years, Chen 2005 (C) ‐ >3 years; Huo 2002 ‐ 11‐17 years, Longfils 2008‐ 6‐21…
1 finding from 1 review
Adverse effects · population aged 2 years and above (Ballot 1989a (C) ‐ > 10 years, Chen 2005 (C) ‐ >3 years; Huo 2002 ‐ 11‐17 years, Longfils 2008‐ 6‐21…
1 finding from 1 review